Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Float Bio raises $140K from MYSC for point-of-care bladder cancer diagnostic kit BLOOM.
Amount Raised
$140,000
Round Type
Pre-Seed
South KoreaBiotechnologyHealth CareTherapeuticsHealth DiagnosticsInvestors
Description
Float Bio, a diagnostic startup, has secured approximately $140,000 (200 million won) in investment from MYSC through the KAIST-MISC Double Impact Fund. The company was selected for MYSC's 2026 EMA Original in-house investment batch program. Float Bio develops disease diagnostic kits using enzyme biomarker amplification technology, with its first product BLOOM being a point-of-care test for bladder cancer screening. The company plans to expand its diagnostic platform to other diseases including periodontal disease and pancreatic cancer.
Fundz sees it the moment Float Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Float Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.